UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                       For the quarter ended May 31, 2007

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

           For the transition period from __________ to ______________

                        Commission File Number 333-140447


                          ONELIFE HEALTH PRODUCTS INC.
             (Exact name of registrant as specified in its charter)

          Nevada                                                 98-0495144
State or other jurisdiction of                                (I.R.S. Employer
incorporation or organization                                Identification No.)

             999 - 3rd Avenue, Suite 3800, Seattle, Washington 98104
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (206) 224-7975

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [X] No [ ]

Number of shares outstanding of the registrant's class of common stock as of
June 29, 2007: 6,000,000

Authorized share capital of the registrant: 50,000,000 common shares, par value
of $0.001

The Company  recorded  $745 in sales  revenue  for the six months  ended May 31,
2007.
<PAGE>
                           FORWARD-LOOKING STATEMENTS

THIS QUARTERLY REPORT ON FORM 10-QSB CONTAINS PREDICTIONS, PROJECTIONS AND OTHER
STATEMENTS ABOUT THE FUTURE THAT ARE INTENDED TO BE "FORWARD-LOOKING STATEMENTS"
WITHIN THE MEANING OF SECTION 21E OF THE  SECURITIES  EXCHANGE  ACT OF 1934,  AS
AMENDED (COLLECTIVELY, "FORWARD-LOOKING STATEMENTS"). FORWARD-LOOKING STATEMENTS
INVOLVE  RISKS AND  UNCERTAINTIES.  A NUMBER OF  IMPORTANT  FACTORS  COULD CAUSE
ACTUAL  RESULTS  TO  DIFFER   MATERIALLY  FROM  THOSE  IN  THE   FORWARD-LOOKING
STATEMENTS. IN ASSESSING FORWARD-LOOKING  STATEMENTS CONTAINED IN THIS QUARTERLY
REPORT ON FORM  10-QSB,  READERS  ARE  URGED TO READ  CAREFULLY  ALL  CAUTIONARY
STATEMENTS  - INCLUDING  THOSE  CONTAINED  IN OTHER  SECTIONS OF THIS  QUARTERLY
REPORT ON FORM 10-QSB.  AMONG SAID RISKS AND  UNCERTAINTIES IS THE RISK THAT THE
COMPANY WILL NOT SUCCESSFULLY  EXECUTE ITS BUSINESS PLAN, THAT ITS MANAGEMENT IS
ADEQUATE TO CARRY OUT ITS BUSINESS PLAN AND THAT THERE WILL BE ADEQUATE  CAPITAL
OR THEY MAY BE UNSUCCESSUFL FOR TECHNICAL, ECONOMIC OR OTHER REASONS.

                         PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

                                                                     Page Number
                                                                     -----------

     Balance Sheets ...............................................      3

     Statements of Operations .....................................      4

     Statement of Stockholder's Equity ............................      5

     Statements of Cash Flows .....................................      6

     Notes to the Financial Statements ............................      7


                                       2
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)

                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                            May 31,          November 30,
                                                             2007               2006
                                                           --------           --------
                                                          (unaudited)
<S>                                                        <C>                <C>
ASSETS

Current assets
  Cash and bank accounts                                   $  7,730           $ 27,763
  Accounts receivable                                            42
  Inventory (Note 4)                                          5,507              5,582
  Rental deposit                                                350                350
                                                           --------           --------

      Total current assets                                   13,629             33,695

Website, net of accumulated amortization (Note 8)            12,072             14,568
                                                           --------           --------

Total assets                                               $ 25,701           $ 48,263
                                                           ========           ========

LIABILITIES AND STOCKHOLDERS' EQUITY


Current liabilities
  Accounts payable and accrued liabilities                 $  3,360           $  1,730
  Due to officer and director (Note 6)                        1,763              2,902
                                                           --------           --------

      Total liabilities                                       5,123              4,632
                                                           --------           --------

Stockholders' equity (Note 5, 6)

Authorized:
  50,000,000 common shares
  Par value $0.001

Issued and outstanding:
  6,000,000 common shares                                     6,000              6,000
Additional paid-in capital                                   49,000             49,000
Deficit accumulated during the development stage            (34,422)           (11,369)
                                                           --------           --------

Total stockholders' equity                                   20,578             43,631
                                                           --------           --------

Total liabilities and stockholders' equity                 $ 25,701           $ 48,263
                                                           ========           ========
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)

                             STATEMENT OF OPERATIONS
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                                                         Cumulative
                                                                                                        Amounts From
                                                                                      Date of             Date of
                                                                                 Incorporation on     Incorporation on
                                                                                 February, 17 2006    February 17, 2006
                              Three Months     Three Months      Six Months             to                   to
                              Ended May 31,    Ended May 31,    Ended May 31,         May 31,              May 31,
                                  2007             2006             2007               2006                 2007
                               ----------       ----------       ----------         ----------           ----------
<S>                            <C>              <C>              <C>                <C>                  <C>
Net sales                      $      578       $       --       $      745         $       --           $      745
Cost of goods sold                    122               --              170                 --                  170
                               ----------       ----------       ----------         ----------           ----------
Gross profit                          456               --              575                 --                  575
                               ----------       ----------       ----------         ----------           ----------

OPERATING EXPENSES
  Amortization                      1,248               --            2,496                 --                2,913
  General & administrative         12,159               96           19,611                 96               27,649
  Marketing & selling                 319               --            1,520                 --                3,088
  Organization                         --              890               --              1,475                1,475
                               ----------       ----------       ----------         ----------           ----------
                                   13,726              986           23,627              1,571               35,125
                               ----------       ----------       ----------         ----------           ----------

Loss from operations              (13,270)            (986)         (23,052)            (1,571)             (34,550)

Interest income                        --               --               --                 --                  128
                               ----------       ----------       ----------         ----------           ----------

Loss before income taxes          (13,270)            (986)         (23,052)            (1,571)             (34,422)

Provision for income taxes             --               --               --                 --                   --
                               ----------       ----------       ----------         ----------           ----------

Net loss                       $  (13,270)      $     (986)      $  (23,052)        $   (1,571)          $  (34,422)
                               ==========       ==========       ==========         ==========           ==========
Basic and diluted loss per
 Common share (1)
                               ==========       ==========       ==========         ==========           ==========

Weighted average number
 of common shares
 outstanding (Note 5)           6,000,000        5,000,000        6,000,000          5,000,000
                               ==========       ==========       ==========         ==========
</TABLE>

----------
(1) less than $0.01

   The accompanying notes are an integral part of these financial statements.

                                       4
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)

                        STATEMENT OF STOCKHOLDERS' EQUITY
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                                      Deficit
                                                                                    Accumulated
                                                    Common Stock      Additional     During the        Total
                                               -------------------     Paid in      Development    Stockholders'
                                               Shares       Amount     Capital         Stage          Equity
                                               ------       ------     -------         -----          ------
<S>                                          <C>            <C>        <C>           <C>             <C>
Inception, February 17, 2006                        --      $   --     $    --       $     --        $     --

Initial capitalization, sale of
 common stock to Directors on
 February 17, 2006                           5,000,000       5,000                                      5,000
Private placement closed July 31, 2006       1,000,000       1,000      49,000                         50,000

Net loss for the year                               --          --          --        (11,369)        (11,369)
                                             ---------      ------     -------       --------        --------
Balance November 30, 2006                    5,000,000       6,000      49,000        (11,369)         43,631

Net loss for the period                             --          --          --        (23,053)        (23,053)
                                             ---------      ------     -------       --------        --------
Balance May 31, 2007                         6,000,000      $6,000     $49,000       $(34,422)       $ 20,578
                                             =========      ======     =======       ========        ========
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       5
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)
                             STATEMENT OF CASH FLOWS
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                                                Cumulative
                                                                                               Amounts From
                                                                                 Date of          Date of
                                                                              Incorporation    Incorporation
                                                                              on February       on February
                                                             Six Months        17, 2006 to      17, 2006 to
                                                            Ended May 31,        May 31,           May 31,
                                                               2007               2006              2007
                                                             --------           -------           --------
<S>                                                          <C>                <C>               <C>
CASH FLOWS USED IN OPERATING ACTIVITIES
  Net loss for the period                                    $(23,052)          $(1,571)          $(34,422)
  Adjustments To Reconcile Net Loss To Net Cash
   Used By Operating Activities
     Amortization expense                                       2,496                --              2,912
  Changes in operating assets and liabilities:
     Accounts receivable                                          (42)               --                (42)
     Inventory                                                     75            (2,670)            (5,507)
     Rental deposit                                                --                --               (350)
     Accounts payable and accrued liabilities                   1,629                --              3,360
     Due to officer and director                               (1,139)               --              1,763
                                                             --------           -------           --------

Net cash used in operating activities                         (20,033)           (4,241)           (32,286)
                                                             --------           -------           --------
CASH FLOWS FROM FINANCING ACTIVITIES
  Proceeds from issuance of common stock                           --             5,000             55,000
                                                             --------           -------           --------

Net cash provided by financing activities                          --             5,000             55,000
                                                             --------           -------           --------
CASH FLOWS USED IN INVESTING ACTIVITIES
  Website                                                          --                --            (14,984)
                                                             --------           -------           --------

Net cash used in investing activities                              --                --            (14,984)
                                                             --------           -------           --------

Increase (decrease) in cash during the period                 (20,033)              759              7,730


Cash, beginning of the period                                  27,763                --                 --
                                                             --------           -------           --------

Cash, end of the period                                      $  7,730           $   759           $  7,730
                                                             ========           =======           ========

Supplemental disclosure with respect to cash flows:
  Cash paid for income taxes                                 $     --           $    --           $     --
  Cash paid for interest                                     $     --           $    --           $     --
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       6
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                   (unaudited)

                                  May 31, 2007


NOTE 1. GENERAL ORGANIZATION AND BUSINESS

The Company was originally incorporated under the laws of the state of Nevada on
February 17, 2006.  The Company has limited  operations  and in accordance  with
SFAS #7, is considered a development stage company, and has had no revenues from
operations to date.

Initial operations have included capital formation,  organization, target market
identification,  new product  development  and marketing  plans.  Management has
commenced with marketing and selling a herbal dietary supplement product that it
recently developed.

These  unaudited  financial  statements  have been prepared in  accordance  with
accounting  principles  generally  accepted in the United States ("US GAAP") for
interim  financial  information.  Accordingly,  they may not  include all of the
information and footnotes required by US GAAP for complete financial statements.
In the opinion of management,  all adjustments  (consisting of normal  recurring
accruals)  considered  necessary  for a fair  presentation  have been  included.
Operating  results  for  the  six-month  period  ended  May  31,  2007,  are not
necessarily  indicative  of the results  that may be expected for the year ended
November 30, 2007.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES

The Company's relevant  accounting policies and procedures are listed below. The
company has adopted a November 30 year end.

ACCOUNTING BASIS

The basis is generally accepted accounting principles.

EARNINGS PER SHARE

In February  1997,  the FASB issued SFAS No. 128,  "Earnings  Per Share",  which
specifies the computation, presentation and disclosure requirements for earnings
(loss) per share for entities  with  publicly  held common  stock.  SFAS No. 128
supersedes the provisions of APB No. 15, and requires the  presentation of basic
earnings (loss) per share and diluted earnings (loss) per share. The Company has
adopted the provisions of SFAS No. 128 effective its inception.

The basic earnings  (loss) per share is calculated by dividing the Company's net
income available to common shareholders by the weighted average number of common
shares during the year. The diluted  earnings  (loss) per share is calculated by
dividing the Company's net income (loss) available to common shareholders by the
diluted  weighted  average  number of shares  outstanding  during the year.  The
diluted  weighted  average  number of shares  outstanding  is the basic weighted

                                       7
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                   (unaudited)

                                  May 31, 2007


NOTE 2. (CONTINUED)

number  of  shares  adjusted  as of the  first of the  year for any  potentially
dilutive debt or equity.

The Company has not issued any options or warrants or similar  securities  since
inception.

DIVIDENDS

The Company has not yet adopted any policy  regarding  payment of dividends.  No
dividends have been paid during the periods shown.

CASH EQUIVALENTS

The Company  considers  all highly  liquid  investments  with  maturity of three
months or less when purchased to be cash equivalents.

INCOME TAXES

Income taxes are provided in accordance  with Statement of Financial  accounting
Standards No. 109 (SFAS 109),  Accounting for Income Taxes. A deferred tax asset
or liability is recorded for all temporary differences between financial and tax
reporting and net operating loss  carryforwards.  Deferred tax expense (benefit)
results  from  the net  change  during  the  year of  deferred  tax  assets  and
liabilities.

Deferred tax assets are reduced by a valuation allowance when, in the opinion of
management,  it is more likely than not that some portion of all of the deferred
tax assets will be realized.  Deferred tax assets and  liabilities  are adjusted
for the effects of changes in tax laws and rates on the date of enactment.

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles
generally  accepted in the United States of America requires  management to make
estimates  and  assumptions  that  affect  the  reported  amounts  of assets and
liabilities  and disclosure of contingent  assets and liabilities at the date of
the financial statements and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.

                                       8
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                   (unaudited)

                                  May 31, 2007

NOTE 2. (CONTINUED)

INVENTORY

Inventory is stated at the lower of cost (determined by the first-in,  first-out
method) or market. See Note 4.

REVENUE RECOGNITION

The company is selling its product  both through an  affiliate  based  marketing
program and  directly to retail  consumers  via the  Internet.  The company will
recognize revenue from product sales when evidence of an order exists at a fixed
or agreed upon price, the product has either been paid for or  collectibility is
reasonably  assured,  and the  product  has  been  shipped  and  risk of loss is
transferred.  Revenue will be recorded as sales of product shipped,  less actual
and estimated  returns,  spoilage  allowances,  rebates and other  expenditures,
which,  using  Generally  Accepted  Accounting  Principles  (GAAP) in the United
States  should  be  accounted  for  as  reductions  of  revenue.  Estimates  and
allowances  are based upon known  claims and an estimate of  additional  returns
when the amount of future returns can be reasonably  estimated.  The company has
established an initial return allowance of 1% of gross sales revenue.

WEBSITE COSTS

Website costs consist of software development costs, which represent capitalized
costs  of  design,  configuration,  coding,  installation  and  testing  of  the
Company's  website up to its  initial  implementation.  Upon  implementation  in
November 2006, the asset is being amortized to expense over its estimated useful
life  of  three  years  using  the   straight-line   method.   Ongoing   website
post-implementation  costs of  operation,  including  training  and  application
maintenance, will be charged to expense as incurred. See Note 8.

NOTE 3. GOING CONCERN

The  accompanying  financial  statements  have been  prepared  assuming that the
Company  will  continue  as a going  concern,  which  contemplates,  among other
things,  the realization of assets and satisfaction of liabilities in the normal
course of business. The Company has net losses from inception to May 31, 2007 of
$(34,422).  The  Company  intends to fund  operations  through  sales and equity
financing   arrangements,   which  may  be  insufficient  to  fund  its  capital
expenditures,  working capital and other cash  requirements  for the year ending
November 30, 2007.

The  ability of the Company to emerge from the  development  stage is  dependent
upon the  Company's  successful  efforts to raise  sufficient  capital  and then

                                       9
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                   (unaudited)

                                  May 31, 2007


NOTE 3. (CONTINUED)

attaining profitable operations.  In response to these problems,  management has
planned the following actions:

     *    The Company recently completed a SB-2 registration statement.

     *    Management intends to raise additional funds through public or private
          placement offerings.

     *    If management  is  unsuccessful  in raising funds in a timely  manner,
          funding by the  company's  controlling  shareholders  of the company's
          budgeted operating shortfall of approximately $30,000 through February
          2008 by unsecured,  interest free debt or private  placement of common
          shares.

     *    Management is currently  funding  marketing efforts to generate sales.
          There can be no assurances, however, that management's expectations of
          future sales will be realized.

These factors, among others, raise substantial doubt about the Company's ability
to continue as a going concern.  These  financial  statements do not include any
adjustments that might result from the outcome of this uncertainty.

NOTE 4. INVENTORY

Inventory consists solely of finished goods.

NOTE 5. STOCKHOLDERS' EQUITY

AUTHORIZED

The Company is authorized to issue 50,000,000  shares of $0.001 par value common
stock. All common stock shares have equal voting rights,  are non-assessable and
have one vote per share.  Voting rights are not cumulative and,  therefore,  the
holders of more than 50% of the common  stock  could,  if they  choose to do so,
elect all of the directors of the Company.

                                       10
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                   (unaudited)

                                  May 31, 2007


NOTE 5. (CONTINUED)

ISSUED AND OUTSTANDING

On February 17, 2006  (inception),  the Company issued  5,000,000  shares of its
common stock to its Directors for cash of $5,000. See Note 6.

On July 31, 2006,  the Company closed a private  placement for 1,000,000  common
shares at a price of $0.05 per share,  or an aggregate  of $50,000.  The Company
accepted subscriptions from 35 offshore non-affiliated investors.

NOTE 6. RELATED PARTY TRANSACTIONS

The  Company's  neither  owns nor  leases  any real or  personal  property.  The
Company's  Directors  provides  office  space free of charge.  The  officers and
directors of the Company are involved in other  business  activities and may, in
the future,  become  involved  in other  business  opportunities.  If a specific
business  opportunity  becomes  available,  such  persons may face a conflict in
selecting  between the Company and their other business  interests.  The Company
has not formulated a policy for the resolution of such conflicts.

On February 17, 2006  (inception),  the Company issued  5,000,000  shares of its
common stock to its Directors for cash of $5,000. See Note 5.

The amount due to an officer and director of $1,763 is for reimbursable expenses
incurred by the company and paid  directly by the  President and CEO. The amount
is unsecured  and does not have any repayment  terms or bear any  interest.  The
amount was paid during the quarter.

NOTE 7. INCOME TAXES

Net  deferred  tax  assets  are $nil.  Realization  of  deferred  tax  assets is
dependent  upon  sufficient   future  taxable  income  during  the  period  that
deductible temporary  differences and carryforwards are expected to be available
to reduce taxable  income.  As the achievement of required future taxable income
is uncertain, the Company recorded a valuation allowance.

                                       11
<PAGE>
                          ONELIFE HEALTH PRODUCTS INC.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                   (unaudited)

                                  May 31, 2007


NOTE 8. WEBSITE

                                              Accumulated
                              Cost            amortization       Net book value
                              ----            ------------       --------------
     Website costs          $14,984             $2,912              $12,072

Website costs are amortized on a straight line basis over 3 years, its estimated
useful life.

NOTE 9. NET OPERATING LOSSES

As of November 30, 2006,  the Company has a net operating  loss carry forward of
approximately  $9,890,  which  will  expire 20 years  from the date the loss was
incurred.  The Company has also additionally incurred an interim loss of $23,052
for the six months ended May 31, 2007.

NOTE 10. OPERATING LEASES AND OTHER COMMITMENTS:

The  Company   currently  has  no  operating  lease  commitments  or  any  other
commitments.

                                       12
<PAGE>
ITEM 2. MANAGEMENT'S PLAN OF OPERATION

GENERAL OVERVIEW

OneLife was  incorporated on February 17, 2006 in the State of Nevada.  We are a
development stage company with limited operations to date.  OneLife's  principal
executive  offices  are  located  at  999 - 3rd  Avenue,  Suite  3800,  Seattle,
Washington  98104.  Our  telephone  number  is (206)  224-7975.  There can be no
assurance that we will be able to operate  profitably in the future,  if at all.
We have  incurred  net  losses  in  each  fiscal  year  since  inception  of our
operations.

OneLife has never declared bankruptcy,  has never been in receivership,  and has
never  been  involved  in  any  legal  action  or  proceedings.  Since  becoming
incorporated,  OneLife has not made any significant  purchase or sale of assets,
nor has it been involved in any mergers, acquisitions or consolidations. Neither
OneLife  nor  its  officers,   directors,   promoters  or  affiliates,  has  had
preliminary  contact or  discussions  with,  nor do we have any  present  plans,
proposals, arrangements or understandings with any representatives of the owners
of any  business or company  regarding  the  possibility  of an  acquisition  or
merger.

We are have focused our business on the  production  and sale of quality  herbal
supplement products to end use consumers via the Internet.  Our target market is
health conscience adult individuals,  with an interest in herbal supplements and
their  inherent  potential  health  benefits.  We have  developed a human immune
system  supplement  product that we have branded  "Daily  Immune  Enhancer  with
Antioxidant  Properties"  designed for relief of symptoms from the common cold &
flu. Our product is available for commercial sale, and our website for sales and
order  fulfillment  has been  available to consumers  since  November  2006.  We
realized our first sales in February, 2007.

We are concentrating  our marketing  efforts in the United States.  Our plan for
the at least  the next 12 months is to  develop  revenues  from the sale of this
product exclusively by sale over the Internet.  Provided we are successful,  and
have the financial and cash  resources to do so, we then plan expand our product
line and develop and sell additional herbal dietary supplement products.  In the
future,  we also plan to expand our business from sales  generation  exclusively
from the  Internet  to having  our  products  sold to  customers  through  other
consumer channels such as retailers, wholesalers, or other direct sale methods

PLAN OF OPERATION

The following discussion of the plan of operation,  financial condition, results
of  operations,  cash flows and  changes in  financial  position  of our Company
should be read in  conjunction  with our most recent  financial  statements  and
notes appearing  elsewhere in this Form 10-QSB; and our SB-2A-5 filed on May 30,
2007.

We developed  the Daily  Immune  Enhancer  with  Antioxidant  Properties  as our
initial  product because  everyone is susceptible to colds and decreased  energy
levels.  A Roper Starch  Worldwide  report  published in 2001 found that dietary
supplements  targeting  cough,  cold,  flu, and sore throat,  enjoyed the second
largest  overall  use by  Americans.  That  same  report  stated  that "The most
prevalent reason consumers use dietary  supplements is to improve overall health
and general well being."

Our business objectives are:

     *    To  become  a  leading   online  retail  herbal   supplement   company
          specializing in creating reliable and effective herbal products
     *    To develop  OneLife  Health  Products as a  recognizable  and reliable
          brand name
     *    To grow  revenues  at a  reasonable  pace  to  become  profitable  and
          maximize long term shareholder value

                                       13
<PAGE>
Our goals over the next 12 months are:

     *    Achieve an average of 1,000 hits per day on OneLife's  website  within
          the next 6 months
     *    Provide increased awareness of the benefits of our herbal supplement
     *    Achieve break even operations over the next 12 months

At present, we have no plans to expand our operations outside of the USA.

We commenced with our plan and budget during this quarter  starting in May 2007.
Our total 12 month expenditure budget is $29,850.

ACTIVITIES DURING THE QUARTER ENDED MAY 31, 2007 UNDER OUR PLAN OF OPERATION

We completed our registration  with the FDA under the Public Health Security and
Bioterrorism Preparedness and Response Act of 2002. Because we are exporting our
product to the USA from  Canada,  we also  engaged an  approved  border  customs
broker to clear our shipments on our behalf, and purchased the necessary bonding
at a cost of $450.00 per annum. This will enable us to export our product to our
customers  on an  expedited  basis with  minimal  disruption.  We also  obtained
commercial general and product liability insurance for our business. It provides
for a maximum  of  $2million  in  coverage  at an  annual  cost of  $5,100.  The
quotation is based on an initial annual gross sales level of $100,000.

In April 2007, we consulted  with our graphic  designers for banner  advertising
for our affiliate  sales program  launch in the August 2007.  Two graphic banner
ads were created, in addition to a text ad, for potential  affiliates to post on
their  websites.  In May  and  June  2007,  we  will  continue  the  set-up  and
development of the affiliate  sales  program.  We plan on listing on several key
programs including:

     *    Commission Junction (www.cj.com)
     *    Linkshare (www.linkshare.com)
     *    Commission Soup (www.commissionsoup.com)
     *    Affiliate Programs (www.affiliateprograms.com)

We believe attracting affiliates can be an effective way to develop sales of our
product and  exposure on a limited  budget.  We will use  graphic  designers  to
develop and design the needed  appropriate  banner ads.  The company `s officers
and directors will draft text unique for each affiliate  program to maximize our
exposure.  This will  include  appropriate  material  for the listing  including
related text, affiliate banners and other related  information,  such as product
benefits,  pricing, etc. Web banners containing this information are then placed
on the affiliate website and when a user clicks on the banner he/she is directed
to our website.

After application and listing on those affiliate sites,  which we have deemed to
be the most important,  we will broaden our search of affiliate program websites
to  further  expand  our  exposure  and thus  sales  potential.  As we  discover
programs,  we will proceed through each of the steps outlined  above.  Assessing
the  significance  of each affiliate  program will come from our research of the
market  place,  what others are using,  popularity  (i.e.,  number of  affiliate
programs  listed) of the  program.  Once  listed,  we will  follow the  activity
generated from each program to gauge its merit.  Since this strategy is a profit
sharing strategy as opposed to a marketing expense strategy, we will not need to
remove our listing from poor performing or unpopular affiliate programs.  It can
be monitored much more passively than that with CPC advertising.

In May 2007, we finished a small $300 print  advertising  campaign in classified
sections of newspapers, health magazines, and or newsletters.  Advertisements in
the smaller  mediums  begin  around $20  depending on word or line count and can
escalate into  thousands of dollars for ads in large  circulation  publications.
Our target is to place 3-4 advertisements to run during May and June 2007.

                                       14
<PAGE>
RESULTS OF OPERATIONS

We generated  $578 in product sales  revenue in our second  quarter and $745 for
the six  months  ended  May 31,  2007.  Our  gross  profit  was  $456  and  $575
respectively.  Our company  posted losses of $13,270 for the second  quarter and
$23,052 for the six months ended May 31, 2007. Comparisons are not meaningful in
this case as our company was  incorporated  on February 17, 2006 and 2006 losses
were generally  attributable to initial  organization  costs.  From inception to
March 31, 2007 we have incurred  losses of $34,422.  The principal  component of
our  losses  for  the six  months  ended  May  31,  2007  included  general  and
administrative   costs  of  $19,611,   marketing   and  selling  of  $1,520  and
amortization of our website of $2,496.

LIQUIDITY AND CASH RESOURCES

At May 31,  2007,  we had  working  capital  of $8,506  compared  to  $29,063 at
November 30, 2006.  At May 31, 2007,  our total assets were $25,701  compared to
$48,263 at November 30, 2006.

We opened the second quarter with approximately  $15,706 in cash. As of the date
hereof,  we  have   approximately   $5,200,  of  which  we  anticipate   needing
approximately  $10,500  for the  balance of  expenses  associated  with our SB-2
Registration Statement. The remaining balance of our budgeted expenditures under
our twelve month plan are approximately $29,850.  Therefore, we presently have a
budgeted shortfall of approximately $35,000.

How long  OneLife will be able to satisfy its cash  requirements  depends on the
success of our Internet based marketing programs in attracting consumers and how
much  revenue our company can  generate  through  resultant  product  sales.  We
believe we can  generate  net  revenues  of  $35-40,000  over the next 12 months
through  the  implementation  of our 12 month  budget.  This would  enable us to
achieve  breakeven  operations,  but  because  of  the  timing  of  our  planned
expenditures under our budget, we require net revenues of approximately  $11,100
prior to July 31, 2007,  $6,900 for the second  quarter ending October 31, 2007,
$9,000 for the third quarter of our budget and $8,000 during the fourth  quarter
budget.  Net revenues are defined as gross sales  revenues  less direct costs to
produce and distribute our products to our customers.

Our per unit net revenue is highly variable due to our current pricing structure
for our  product.  Our net  revenues  will vary  significantly  depending on the
following factors:

     *    Affiliate sales versus direct retail sales. We are currently  offering
          affiliates a 50%  commission  on gross  selling  price after  quantity
          discounts that we do not have to incur for direct retail sales.
     *    The number of single unit sales versus  multiple unit sales.  We offer
          price discounts for purchases of multiple units that vary from 17% for
          2 unit  purchases  to  33%  for 6 unit  purchases,  whether  purchased
          through affiliates or direct from our website.
     *    The ongoing cost to procure raw materials and manufacture our product.
          Procurement  of all of our raw  materials and the  manufacture  of our
          product is all conducted by third parties. If our current manufacturer
          or the  industry  raises  its  prices or if order  lead  times  change
          significantly,  we may experience  significant  cost increases for our
          product or may not even have product available for sale
     *    Shipping  costs.  Our  current  shipping  costs are $7.95 for 1-2 unit
          sales  and  $10.95  for  3-6  unit  sales.  Our  shipping  costs  vary
          significantly  according  to the  number of units  shipped.  Under our
          current affiliate  program,  we do not incur shipping costs. They form
          part of the commission we pay affiliates who are  responsible for this
          cost.

Our achievement of breakeven  operations for the next 12 months does not include
compensation  costs for our officers and  directors,  or costs for our premises,
which are currently  provided free of charge by our officers and directors.  Our
officers  and  directors  will  continue  to  be  responsible  for  all  of  our
administrative and regulatory  activities,  the marketing of our product,  order
fulfillment,  management of our website and  affiliate  program for at least the
first year of  operations.  If we were to compensate  our officers and directors

                                       15
<PAGE>
for these activities,  we believe we would incur costs in excess of $100-120,000
annually.  We have not budgeted to hire any employees  within the next 12 months
and will only do so if our order fulfillment and distribution  activities become
too  much for Mr.  McFarland  to  perform  himself,  and  there  are  sufficient
financial  resources  to do so. This would be a clerical  position  and we would
expect that we could hire someone for  approximately  $25,000 on an annual basis
should the need arise. We are not planning to relocate our executive  offices or
order fulfillment  operations in the foreseeable future and have not budgeted to
do so.  If we were to rent  comparable  space,  we  believe  we  could do so for
approximately $1,200-1,500 monthly.

If we fail to generate sufficient net revenues, we will need to raise additional
capital  to  continue  our  operations  thereafter.  We  cannot  guarantee  that
additional funding will be available on favorable terms, if at all. If we cannot
secure additional  financing from outside sources,  our directors have committed
to fund any  shortfall  under our 12 month  budget by either (i);  an  unsecured
shareholder  loan without  interest,  which would not be repayable until we have
the financial  resources  available to do so, but subject to a minimum term of 2
years,  or (ii);  through a private  placement  of common  shares  that would be
priced at a mimimum of $0.10 per share,  or the market price of our common stock
if our  shares are  posted  for  trading  on a public  market at the time of the
subscription.  Any further  shortfall  will effect our ability to expand or even
continue our operations.  We cannot  guarantee that  additional  funding will be
available on favorable terms, if at all.

ITEM 3. CONTROLS AND PROCEDURES

As required  by Rule  13a-15  under the  Exchange  Act,  we have  carried out an
evaluation  of the  effectiveness  of the design and  operation of our company's
disclosure  controls and  procedures as of the end of the period covered by this
quarterly  report for the six months ended May 31,  2007.  This  evaluation  was
carried out under the  supervision and with the  participation  of our company's
management, including our company's president and chief executive officer. Based
upon that  evaluation,  our  company's  president  and chief  executive  officer
concluded that our company's disclosure controls and procedures are effective as
at the end of the period  covered by this report.  There have been no changes in
our internal  controls over financial  reporting  that occurred  during our most
recent fiscal quarter that have materially affected, or are reasonably likely to
materially affect our internal controls over financial reporting.

Disclosure  controls and procedures are controls and other  procedures  that are
designed to ensure that  information  required to be disclosed in our  company's
reports  filed or  submitted  under the  Exchange  Act is  recorded,  processed,
summarized and reported, within the time periods specified in the Securities and
Exchange  Commission's  rules and  forms.  Disclosure  controls  and  procedures
include,  without  limitation,  controls and procedures  designed to ensure that
information  required to be disclosed in our  company's  reports filed under the
Exchange Act is  accumulated  and  communicated  to  management,  including  our
company's president as appropriate, to allow timely decisions regarding required
disclosure.

                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

                                       16
<PAGE>
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5.  OTHER INFORMATION

On June 7,  2007  the SEC  declared  our  registration  statement  on Form  SB-2
effective,  which  registered  1,000,000  common  shares for  resale  held by 35
non-affiliated investors.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

(a) Pursuant to Rule 601 of Regulation  SB, the following  exhibits are included
herein or incorporated by reference.

     Exhibit
     Number          Description

     3.1       Articles of Incorporation*
     3.2       By-laws*
     31.1      Certification of CEO Pursuant to 18 U.S.C. ss. 1350, Section 302
     31.2      Certification of CFO Pursuant to 18 U.S.C. ss. 1350, Section 302
     32.1      Certification Pursuant to 18 U.S.C. ss.1350, Section 906
     32.2      Certification Pursuant to 18 U.S.C. ss.1350, Section 906

----------
*    Incorporated by reference to our SB2  Registration  Statement,  File Number
     333-140447

Reports on Form 8-K

None.

                                       17
<PAGE>
                                   SIGNATURES

Pursuant to the  requirements of Section 13 or 15(d) of the Securities  Exchange
Act of 1934,  the  registrant  has duly  caused  this report to be signed on its
behalf by the undersigned, thereunto duly authorized, on this day of July, 2007.

                               ONELIFE HEALTH PRODUCTS, INC.


Date: July 11, 2007            By: /s/ Dan McFarland
                                  ----------------------------------------------
                               Name:  Dan McFarland
                               Title: President/CEO, principal executive officer


Date: July 11, 2007            By: /s/ Rakesh Chehil
                                  ----------------------------------------------
                               Name:  Rakesh Chehil
                               Title: Chief Financial Officer, principal
                                      financial officer

                                       18